Focal Segmental Glomerulosclerosis Market to Reach USD 2.3 Billion by 2036, Driven by Rising Kidney Disease Burden and Advancements in Targeted Therapies at 5.8% CAGR

The global focal segmental glomerulosclerosis (FSGS) market was valued at US$ 1.2 Bn in 2025 and is projected to reach US$ 2.3 Bn by 2036, expanding at a CAGR of 5.8% from 2026 to 2036. Growth in the market is being supported by the increasing prevalence of kidney disorders, rising healthcare expenditure, greater investment in clinical research, and the development of specialized diagnostic and therapeutic solutions for FSGS.

Focal segmental glomerulosclerosis is a progressive kidney disease characterized by scarring of the glomeruli, which are responsible for filtering waste from the blood. The condition can impair kidney function and result in proteinuria and other complications. Increasing awareness of progressive renal diseases and advances in disease-specific treatments are creating new opportunities for pharmaceutical companies and healthcare providers.

The treatment landscape is also evolving as companies invest in targeted therapies, genetic approaches, stem cell research, and specialized diagnostic technologies. Product approvals and clinical development programs are further contributing to market expansion.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=31505

Analyst Viewpoint

Increasing prevalence of kidney disorders is a key factor supporting growth of the global FSGS market. Individuals with underlying kidney disease may face a higher risk of developing progressive renal complications, creating continued demand for diagnosis and treatment. At the same time, advances in research and development are expanding the therapeutic landscape through approaches such as targeted therapies, stem cell therapy, and genetic therapies.

Companies operating in the market are increasingly focused on developing specialized diagnostic tests and treatments that can improve disease management and patient outcomes. Product launches, regulatory approvals, clinical trials, and strategic collaborations are also becoming important components of competitive strategies as pharmaceutical companies seek to expand their presence in the FSGS treatment landscape.

Market Introduction

Focal segmental glomerulosclerosis is a type of kidney disease characterized by the formation of scar tissue on the glomeruli, the filtering structures of the kidneys responsible for removing waste from the body. Damage to these structures can impair filtration and result in abnormal protein loss through urine.

FSGS may be associated with symptoms such as frothy urine, excessive fluid retention, susceptibility to infections, and fatty casts in urine. Common factors associated with the condition include underlying kidney diseases, obesity, excessive intake of certain drugs or steroids, and inherited genetic factors. The condition affects men more frequently than women, while patients may also experience weight gain associated with elevated blood lipid levels, reduced appetite, fatigue, and accumulation of excess fluid.

Diagnosis generally involves a combination of imaging and laboratory investigations. Ultrasound and CT scans can help identify kidney abnormalities, while laboratory testing can evaluate creatinine levels and kidney function. Urine testing is used to identify proteinuria, and a renal biopsy may be performed to confirm FSGS by examining a small sample of kidney tissue under a microscope.

The increasing burden of kidney disease, together with improvements in diagnostic capabilities and growing investment in therapeutic research, is expected to support the development of the FSGS market during the forecast period.

Increasing Prevalence of Kidney Disorders Fuels Market Demand

The growing prevalence of kidney disorders is an important factor supporting demand for FSGS diagnosis and treatment. Kidney infections are a type of urinary tract infection that can originate in the urethra or bladder and travel to one or both kidneys. More broadly, chronic and progressive kidney disorders represent a substantial healthcare burden and can increase the need for advanced renal disease management.

According to the Centers for Disease Control and Prevention, approximately 37 million U.S. adults, or 14% of the adult population, are estimated to have chronic kidney disease. CKD prevalence increases substantially with age, affecting approximately 6% of adults aged 18 to 44 years, 13% of those aged 45 to 64 years, and 34% of adults aged 65 years and older.

The substantial burden of chronic kidney disease and other underlying renal disorders is increasing the need for effective diagnosis and treatment of progressive kidney diseases. As healthcare systems seek to address the growing population affected by renal disorders, demand for therapies targeting FSGS is expected to increase.

Greater awareness of kidney disease, improvements in diagnostic testing, and increasing recognition of proteinuric and progressive renal conditions can further support identification of patients requiring specialized care. These developments are expected to contribute to market expansion over the forecast period.

Rising Healthcare Expenditure Boosts Market Progress

Increasing healthcare expenditure is supporting the development and accessibility of medications and advanced treatment options for FSGS. Greater investment in pharmaceutical research, clinical trials, and drug development is providing companies with resources to investigate new therapeutic approaches for rare and progressive kidney diseases.

According to the Office for National Statistics, total healthcare expenditure in the U.K. reached approximately £317 billion in 2024, representing a 6.5% increase in nominal terms and a 2.4% increase in real terms compared with 2023. Government-financed healthcare represented the majority of expenditure, reaching approximately £258 billion in 2024.

Total pharmaceutical expenditure in the U.K. was estimated at approximately £35.9 billion in 2023 at 2024 prices, highlighting the continued importance of medicines within healthcare expenditure. Sustained growth in healthcare spending and investment in pharmaceutical therapies can facilitate the development and adoption of advanced treatments for chronic and rare renal disorders.

Growing funding for clinical research is particularly important for FSGS because the condition requires specialized approaches to diagnosis and disease management. Increased availability of financial resources for research institutions, pharmaceutical companies, and clinical investigators is expected to create opportunities for the development of disease-specific therapies.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=31505

North America Leads the FSGS Market

North America accounted for the largest share of the global focal segmental glomerulosclerosis market in 2025. The region benefits from developed healthcare systems, modern medical facilities, advanced diagnostic technologies, and comparatively high adoption of innovative treatment approaches.

The U.S. represents the largest FSGS market in North America, supported by a significant diagnosed patient population and greater awareness of the disease. FSGS is estimated to affect approximately 40,000 people in the U.S., highlighting an unmet medical need among patients with progressive kidney disease.

Recent real-world evidence studies estimated the annual standardized prevalence of FSGS in the U.S. at approximately 212.6 cases per million population during 2016–2020, with prevalence increasing over the study period. The growing disease burden among high-risk populations and the development of targeted treatment options are expected to support the U.S. market.

North America also benefits from substantial clinical research activity. Pharmaceutical and biotechnology companies frequently conduct clinical trials in the U.S. due to the country's established healthcare infrastructure and research ecosystem. Continued investment in clinical development and specialized renal care is therefore expected to strengthen the regional FSGS market.

Advancements in FSGS Research Create Growth Opportunities

Increasing research and development activity is creating opportunities for companies operating in the FSGS market. Pharmaceutical and biotechnology companies are investigating specialized therapies designed to address disease mechanisms and improve outcomes for patients with progressive kidney disease.

The development of targeted therapies, genetic approaches, stem cell-based research, and other emerging treatment strategies could broaden the available options beyond conventional disease management. Specialized diagnostic tests may also support earlier and more precise identification of patients with FSGS.

The growing focus on precision medicine is particularly relevant to rare and progressive renal diseases because disease mechanisms and patient responses can vary. Research into immune, genetic, and other biological pathways is therefore contributing to a broader development pipeline.

Strategic partnerships and collaborations between pharmaceutical companies, biotechnology firms, and research organizations can further accelerate clinical development and commercialization. As companies continue investing in product development, clinical trials, and regulatory submissions, the expansion of disease-specific treatment options is expected to create new commercial opportunities.

Competitive Landscape

The global focal segmental glomerulosclerosis market is characterized by increasing investment in research and development, clinical-stage drug development, strategic partnerships, and product approvals. Leading companies are focusing on expanding their therapeutic portfolios and developing specialized solutions for progressive kidney disease.

The competitive environment is being influenced by the growing focus on disease-specific treatment approaches and the emergence of targeted therapies. Companies are also pursuing collaborations and partnerships to strengthen their research capabilities, expand product portfolios, and accelerate clinical development.

Prominent companies operating in the market include Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Travere Therapeutics, AbbVie, Inc., Novartis AG, Pfizer, Inc., AstraZeneca plc., Sanofi S.A., GlaxoSmithKline plc., and Teva Pharmaceutical Industries Ltd.

These companies are profiled based on company overview, business strategies, financial performance, business segments, product portfolios, sales footprint, and recent developments.

Key Developments

In April 2026, Travere Therapeutics received FDA approval for FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis. According to the supplied market information, the approval made FILSPARI the first FDA-approved disease-specific therapy for FSGS. The approval was supported by results from the Phase III DUPLEX study, which demonstrated reductions in proteinuria and preservation of kidney-function indicators compared with irbesartan. The development represents an important change in the FSGS treatment landscape, which has historically included supportive care and off-label immunosuppressive therapies.

In 2025, Vertex Pharmaceuticals advanced its kidney disease pipeline through clinical development of povetacicept (ALPN-303), a dual BAFF/APRIL inhibitor being investigated for autoimmune kidney diseases, including IgA nephropathy and other immune-mediated renal disorders. Development of therapies targeting complement and immune pathways reflects increasing interest in precision medicine approaches for progressive kidney diseases with overlapping disease mechanisms.

In 2025, Otsuka Pharmaceutical continued development and commercialization activities within its nephrology portfolio, focusing on targeted therapies for progressive proteinuric kidney disorders. Increasing participation by major pharmaceutical companies in rare renal disease therapies is contributing to a broader competitive pipeline beyond traditional supportive treatment approaches.

Market Segmentation

The global focal segmental glomerulosclerosis market is segmented by disease type and disease management. Based on disease type, the market is divided into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis.

By disease management, the market is categorized into diagnosis and treatment. Diagnosis includes kidney biopsy, creatinine testing, and other diagnostic approaches. Treatment encompasses drug therapy, dialysis, and kidney transplantation.

Geographically, the market covers North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. Countries covered include the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China, India, Australia and New Zealand, Brazil, Mexico, GCC countries, and South Africa.

Future Outlook

The global focal segmental glomerulosclerosis market is projected to grow from US$ 1.2 Bn in 2025 to US$ 2.3 Bn by 2036, expanding at a CAGR of 5.8% from 2026 to 2036. Rising prevalence of kidney disorders, increasing healthcare expenditure, greater clinical research activity, and growing development of targeted therapies are expected to remain important factors shaping the market.

North America is expected to remain a significant regional market due to advanced healthcare infrastructure, high disease awareness, extensive clinical research activity, and the presence of pharmaceutical and biotechnology companies. The U.S. is particularly important because of its diagnosed patient population and increasing availability of disease-specific treatment options.

Meanwhile, advancements in precision medicine, targeted therapies, genetic research, and specialized diagnostics could create new opportunities for market participants. Regulatory approvals and increasing investment in rare and progressive renal diseases are also expected to influence the competitive landscape.

As treatment options continue to evolve and healthcare systems increase their focus on progressive kidney disease management, the FSGS market is expected to experience steady expansion through 2036.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=31505<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Kidney Transplant Market

Rapid Microbiology Testing Market

Laboratory Robotics Market

Kidney Cancer Diagnostics Market

Vendor Neutral Archive (VNA) Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com